ea0077op2.3 | Adrenal and Cardiovascular | SFEBES2021
Warmington Emily
, Smith Gabrielle
, Chortis Vasileios
, Khan Sana
, Lippert Juliane
, Hantel Constanze
, Liang Raimunde
, Kiseljak-Vassiliades Katja
, Wierman Margaret
, Altieri Barbara
, Fassnacht Martin
, Foster Paul
, Ronchi Cristina
Adrenocortical carcinoma (ACC) is an aggressive malignancy with limited treatment options. We identified polo-like kinase 1 (PLK1) as one of the most overexpressed genes and potential drug target in ACC. PLK1 inhibitors (PLK1i) are under evaluation in clinical trials for other malignancies, being more effective in TP53-mutated tumours. Here we test PLK1i efficacy in four ACC cell lines with different genetic background. Efficacy of three PLK1i (i.e. Volaserti...